These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 22162535

  • 1. Pharmacokinetics of the soluble guanylate cyclase activator cinaciguat in individuals with hepatic impairment.
    Frey R, Scheerans C, Blunck M, Mück W, Gnoth MJ, Unger S, Schmidt A, Wensing G.
    J Clin Pharmacol; 2012 Nov; 52(11):1714-24. PubMed ID: 22162535
    [Abstract] [Full Text] [Related]

  • 2. Assessment of the effects of renal impairment on the pharmacokinetics of the soluble guanylate cyclase activator cinaciguat after a single intravenous dose.
    Lettieri JT, Scheerans C, Blunck M, Mazzu AL, Frey R, Mück W, Sundaresan PR.
    J Clin Pharmacol; 2012 Aug; 52(8):1240-7. PubMed ID: 21868716
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers.
    Frey R, Mück W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G.
    J Clin Pharmacol; 2008 Dec; 48(12):1400-10. PubMed ID: 18779378
    [Abstract] [Full Text] [Related]

  • 4. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure.
    Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J, Mueck W, Unger S, Wensing G, Frey R.
    Circulation; 2009 Jun 02; 119(21):2781-8. PubMed ID: 19451356
    [Abstract] [Full Text] [Related]

  • 5. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
    Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A, COMPOSE Investigators and Coordinators.
    Eur J Heart Fail; 2012 Sep 02; 14(9):1056-66. PubMed ID: 22713287
    [Abstract] [Full Text] [Related]

  • 6. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.
    Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, Mebazaa A.
    Eur Heart J; 2013 Jan 02; 34(1):57-67. PubMed ID: 22778174
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure.
    Mueck W, Frey R.
    Clin Pharmacokinet; 2010 Jan 02; 49(2):119-29. PubMed ID: 20067336
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.
    Korkmaz S, Radovits T, Barnucz E, Hirschberg K, Neugebauer P, Loganathan S, Veres G, Páli S, Seidel B, Zöllner S, Karck M, Szabó G.
    Circulation; 2009 Aug 25; 120(8):677-86. PubMed ID: 19667237
    [Abstract] [Full Text] [Related]

  • 9. Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass.
    Radovits T, Korkmaz S, Miesel-Gröschel C, Seidel B, Stasch JP, Merkely B, Karck M, Szabó G.
    Eur J Cardiothorac Surg; 2011 Feb 25; 39(2):248-55. PubMed ID: 20591683
    [Abstract] [Full Text] [Related]

  • 10. Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta.
    Korkmaz S, Loganathan S, Mikles B, Radovits T, Barnucz E, Hirschberg K, Li S, Hegedüs P, Páli S, Weymann A, Karck M, Szabó G.
    J Cardiovasc Pharmacol Ther; 2013 Jan 25; 18(1):70-7. PubMed ID: 22914857
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation.
    Sawabe T, Chiba T, Kobayashi A, Nagasaka K, Aihara K, Takaya A.
    Pharmacol Res Perspect; 2019 Apr 25; 7(2):e00463. PubMed ID: 30873284
    [Abstract] [Full Text] [Related]

  • 13. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
    Schöller-Gyüre M, Kakuda TN, De Smedt G, Woodfall B, Berckmans C, Peeters M, Hoetelmans RM.
    Clin Ther; 2010 Feb 25; 32(2):328-37. PubMed ID: 20206790
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers.
    Stangier J, Su CA, Schöndorfer G, Roth W.
    J Clin Pharmacol; 2000 Dec 25; 40(12 Pt 1):1355-64. PubMed ID: 11185634
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
    Takeuchi K, Sugiura T, Umeda S, Matsubara K, Horikawa M, Nakamichi N, Silver DL, Ishiwata N, Kato Y.
    Drug Metab Dispos; 2011 Jun 25; 39(6):1088-96. PubMed ID: 21422191
    [Abstract] [Full Text] [Related]

  • 16. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
    Bauman JW, Vincent CT, Peng B, Wire MB, Williams DD, Park JW.
    J Clin Pharmacol; 2011 May 25; 51(5):739-50. PubMed ID: 20663991
    [Abstract] [Full Text] [Related]

  • 17. Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure.
    Tamargo J, Duarte J, Caballero R, Delpón E.
    Curr Opin Investig Drugs; 2010 Sep 25; 11(9):1039-47. PubMed ID: 20730699
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q, Iyer GR, Verhaeghe T, Truyen L.
    J Clin Pharmacol; 2002 Apr 25; 42(4):428-36. PubMed ID: 11936568
    [Abstract] [Full Text] [Related]

  • 19. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin.
    Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL.
    Pharmacotherapy; 2010 Jan 25; 30(1):35-42. PubMed ID: 20030471
    [Abstract] [Full Text] [Related]

  • 20. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
    Baird-Bellaire S, Behrle JA, Parker VD, Patat A, Paul J, Nichols AI.
    Clin Ther; 2013 Jun 25; 35(6):782-94. PubMed ID: 23623756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.